Ross Cummings

Advances in Gene Therapy: The End of the Era of Incurable Genetic Diseases?

Editing an individual’s DNA, to prevent or treat a genetic disease, at one time seemed an impossible task. Remarkably, we are now living in an age of medical development where decades of laboratory research have been successfully translated into gene therapies suitable for human use. Gene therapy may, for example,...

Read more

The President of the EPO is determined to prevent patents issuing directed to plants obtained by essentially biological processes

In a notice published yesterday, the President of the EPO has decided to stay any examination or opposition proceedings at the EPO where the patent application or patent in question claims a plant or animal exclusively obtained by means of an essentially biological process. This decision has been taken to...

Read more

The President of the EPO turns up the heat on the Boards of Appeal in the debate over patentability of products of essentially biological processes

Following on from my previous report on the EPO Administrative Council’s new Rule 28(2) explicitly excluding products of “essentially biological processes” from patentability, this story has taken some interesting new turns. New Rule 28(2) was billed as a “clarification” of the meaning of Article 53(b) EPC but in February in...

Read more

UK Biotech patent application searches: cheap as DNA chips!

Biotech patent applicants filing their priority applications at the UK Intellectual Property Office (UKIPO) could now benefit from significant savings in search fees. This is another great reason to file your first applications in the UK. The UKIPO has today officially announced that they will be working with the European...

Read more

FierceBiotech Executive Summit

On Tuesday 30 October, Ross Cummings will be attending the FierceBiotech Executive Summit at the Royal Society of Medicine. The half-day summit will gather industry experts to discuss the infrastructures of biomedical sciences across the UK and the challenges and opportunities to the life sciences sector amid a time of...

Read more